Claudin‐2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
Open Access
- 14 October 2013
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 8 (1) , 119-128
Abstract
Background: Predicting any future metastatic site of early‐stage breast cancer is important as it significantly influences the prognosis of advanced disease. This study aimed at investigating the potential of claudin‐2, over‐expressed in breast cancer liver metastases, as a biomarker for predicting liver metastatic propensity in primary breast cancer.Methods: Claudin‐2 expression was analyzed in two independent cohorts. Cohort 1 included 304 women with metastatic breast cancer diagnosed between 2002 and 2007, while cohort 2 included 237 premenopausal women with early‐stage node‐negative breast cancer diagnosed between 1991 and 1994. Global transcriptional profiling of fine‐needle aspirates from metastases was performed, followed by immunohistochemical analyses in archival primary tumor tissue. Associations between claudin‐2 expression and relapse site were assessed by univariable and multivariable Cox regression models including conventional prognostic factors. Two‐sided statistical tests were used.Results: CLDN2 was significantly up‐regulated (P < 0.001) in liver metastases compared to other metastatic sites. Claudin‐2 protein was more frequently expressed in primary tumors from patients who subsequently developed liver metastases (P = 0.02) and high expression was associated with a shorter metastasis‐free interval (cohort 1, HR = 1.4, 95% CI = 1.0–1.9; cohort 2, HR = 2.2, 95% CI = 1.3–3.5). Specifically, a significantly shorter interval between primary tumor diagnosis and liver‐specific recurrence was observed among patients with high levels of claudin‐2 expression in the primary tumor (cohort 1, HR = 2.3, 95% CI = 1.3–3.9).Conclusion: These results suggest a novel role for claudin‐2 as a prognostic biomarker with the ability to predict not only the likelihood of a breast cancer recurrence, but more interestingly, the liver metastatic potential of the primary tumor.Keywords
This publication has 41 references indexed in Scilit:
- Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trialBreast Cancer Research and Treatment, 2011
- Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapseBreast Cancer Research and Treatment, 2011
- Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activationOncogene, 2011
- Genes that mediate breast cancer metastasis to the brainNature, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsNucleic Acids Research, 2008
- Epidermal growth factor receptor and claudin‐2 participate in A549 permeability and remodeling: Implications for non‐small cell lung cancer tumor colonizationMolecular Carcinogenesis, 2008
- Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformationLaboratory Investigation, 2008
- Prognostic factors in 1038 women with metastatic breast cancerAnnals of Oncology, 2008